Can a simple blood test guide septic shock treatment?
NCT ID NCT05824767
First seen Feb 05, 2026
Summary
This completed pilot study looked at whether two blood markers, renin and DPP3, can predict how well patients with septic shock respond to the drug angiotensin II compared to standard blood pressure medicines. Forty adults with persistent low blood pressure despite standard treatment were randomly assigned to receive either angiotensin II or usual care. The goal was to see if these markers could help doctors choose the best treatment for each patient.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEPTIC SHOCK are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of New Mexico Health Sciences Center
Albuquerque, New Mexico, 87106, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Angiotensin II (Giapreza)
What this could lead to
If successful, this could help doctors identify which septic shock patients will benefit most from angiotensin II, potentially improving treatment decisions.
What could go wrong
This is a small, single-center pilot study with only 40 participants, so results may not apply broadly. The study is unblinded, which can introduce bias.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.